In the past week, RVPH stock has gone down by -11.86%, with a monthly decline of -45.55% and a quarterly plunge of -50.94%. The volatility ratio for the week is 9.34%, and the volatility levels for the last 30 days are 10.39% for Reviva Pharmaceuticals Holdings Inc The simple moving average for the past 20 days is -25.95% for RVPH’s stock, with a -24.33% simple moving average for the past 200 days.
Is It Worth Investing in Reviva Pharmaceuticals Holdings Inc (NASDAQ: RVPH) Right Now?
RVPH has 36-month beta value of -0.02. Analysts have mixed views on the stock, with 3 analysts rating it as a “buy,” 3 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for RVPH is 41.63M, and currently, short sellers hold a 9.10% ratio of that float. The average trading volume of RVPH on March 14, 2025 was 2.48M shares.
RVPH) stock’s latest price update
Reviva Pharmaceuticals Holdings Inc (NASDAQ: RVPH) has experienced a decline in its stock price by -9.57 compared to its previous closing price of 1.15. However, the company has seen a fall of -11.86% in its stock price over the last five trading days. globenewswire.com reported 2025-02-04 that CUPERTINO, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference, taking place virtually February 11-12, 2025.
Analysts’ Opinion of RVPH
Many brokerage firms have already submitted their reports for RVPH stocks, with ROTH MKM repeating the rating for RVPH by listing it as a “Buy.” The predicted price for RVPH in the upcoming period, according to ROTH MKM is $12 based on the research report published on September 20, 2023 of the previous year 2023.
The Benchmark Company, on the other hand, stated in their research note that they expect to see RVPH reach a price target of $17. The rating they have provided for RVPH stocks is “Speculative Buy” according to the report published on June 08th, 2023.
H.C. Wainwright gave a rating of “Buy” to RVPH, setting the target price at $10 in the report published on January 24th of the previous year.
RVPH Trading at -38.87% from the 50-Day Moving Average
After a stumble in the market that brought RVPH to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -75.70% of loss for the given period.
Volatility was left at 10.39%, however, over the last 30 days, the volatility rate increased by 9.34%, as shares sank -44.39% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -42.22% lower at present.
During the last 5 trading sessions, RVPH fell by -11.86%, which changed the moving average for the period of 200-days by -28.28% in comparison to the 20-day moving average, which settled at $1.4045. In addition, Reviva Pharmaceuticals Holdings Inc saw -42.54% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for RVPH
The total capital return value is set at 3.48. Equity return is now at value -1806.28, with -512.93 for asset returns.
Based on Reviva Pharmaceuticals Holdings Inc (RVPH), the company’s capital structure generated -0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -401.44. The debt to equity ratio resting at -0.01. The interest coverage ratio of the stock is 5205.61.
Currently, EBITDA for the company is -39.5 trillion with net debt to EBITDA at 0.22. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.39.
Conclusion
To put it simply, Reviva Pharmaceuticals Holdings Inc (RVPH) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
